NMD Pharma: SYNAPSE-CMT Phase 2a Clinical Study Data Presented in Late-Breaking Oral Presentation at 2026 PNS Annual Meeting

Aarhus, Denmark, 17 June 2026 - NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announces that further safety an ...
MarketWatch

NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant ...

The MarketWatch News Department was not involved in the creation of this content. -- NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in ...